JP2010529132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529132A5 JP2010529132A5 JP2010511212A JP2010511212A JP2010529132A5 JP 2010529132 A5 JP2010529132 A5 JP 2010529132A5 JP 2010511212 A JP2010511212 A JP 2010511212A JP 2010511212 A JP2010511212 A JP 2010511212A JP 2010529132 A5 JP2010529132 A5 JP 2010529132A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- free
- alkyl
- pharmaceutically acceptable
- salt form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 150000003839 salts Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 206010002022 amyloidosis Diseases 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 238000009825 accumulation Methods 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 208000003808 Amyloid Neuropathies Diseases 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 208000009798 Craniopharyngioma Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 3
- 206010014967 Ependymoma Diseases 0.000 claims 3
- 208000021309 Germ cell tumor Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000007641 Pinealoma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 206010014599 encephalitis Diseases 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 206010027191 meningioma Diseases 0.000 claims 3
- 210000005036 nerve Anatomy 0.000 claims 3
- 208000024724 pineal body neoplasm Diseases 0.000 claims 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010062767 Hypophysitis Diseases 0.000 claims 2
- 208000024777 Prion disease Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003635 pituitary gland Anatomy 0.000 claims 2
- 102000013498 tau Proteins Human genes 0.000 claims 2
- 108010026424 tau Proteins Proteins 0.000 claims 2
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 102400000269 Amyloid protein A Human genes 0.000 claims 1
- 101710144835 Amyloid protein A Proteins 0.000 claims 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- SLCWCSUXHGTXGQ-UHFFFAOYSA-N CC1CCN(Cc(cc2)ccc2NC(c2cc(Nc3nc(-c4cccc(C(F)(F)F)c4)ccn3)cnc2)=O)CC1 Chemical compound CC1CCN(Cc(cc2)ccc2NC(c2cc(Nc3nc(-c4cccc(C(F)(F)F)c4)ccn3)cnc2)=O)CC1 SLCWCSUXHGTXGQ-UHFFFAOYSA-N 0.000 description 1
- SNNDMEXVQLHLTL-UHFFFAOYSA-N CC1CCN(Cc(cc2)ccc2NC(c2cc(Nc3nc(-c4ccccc4)c(C)cn3)cnc2)=O)CC1 Chemical compound CC1CCN(Cc(cc2)ccc2NC(c2cc(Nc3nc(-c4ccccc4)c(C)cn3)cnc2)=O)CC1 SNNDMEXVQLHLTL-UHFFFAOYSA-N 0.000 description 1
- DCALOKPQJGPWJM-UHFFFAOYSA-N CC1CCN(Cc(cc2)ccc2NC(c2cc(Nc3nc(-c4ccccc4)ccn3)cnc2)=O)CC1 Chemical compound CC1CCN(Cc(cc2)ccc2NC(c2cc(Nc3nc(-c4ccccc4)ccn3)cnc2)=O)CC1 DCALOKPQJGPWJM-UHFFFAOYSA-N 0.000 description 1
- AXWSNYFKBQAFPP-UHFFFAOYSA-N CC1CCN(Cc(cc2)ccc2NC(c2ccnc(Nc3nc(-c4cccc(C(F)(F)F)c4)ccn3)c2)=O)CC1 Chemical compound CC1CCN(Cc(cc2)ccc2NC(c2ccnc(Nc3nc(-c4cccc(C(F)(F)F)c4)ccn3)c2)=O)CC1 AXWSNYFKBQAFPP-UHFFFAOYSA-N 0.000 description 1
- PMHBYOCIPGXBHI-UHFFFAOYSA-N CCN1CCN(Cc(cc2)ccc2C(Nc2cc(Nc3nc(-c4ccccc4)ccn3)c(C)nc2)=O)CC1 Chemical compound CCN1CCN(Cc(cc2)ccc2C(Nc2cc(Nc3nc(-c4ccccc4)ccn3)c(C)nc2)=O)CC1 PMHBYOCIPGXBHI-UHFFFAOYSA-N 0.000 description 1
- KTVMGKYOHAFKFE-UHFFFAOYSA-N CCN1CCN(Cc(cc2)ccc2C(Nc2cc(Nc3nc(-c4cnccc4)ccn3)c(C)nc2)=O)CC1 Chemical compound CCN1CCN(Cc(cc2)ccc2C(Nc2cc(Nc3nc(-c4cnccc4)ccn3)c(C)nc2)=O)CC1 KTVMGKYOHAFKFE-UHFFFAOYSA-N 0.000 description 1
- DDROEHOVYPZJIV-UHFFFAOYSA-N Cc(ncc(NC(c1ccc(CC2CCN(C)CC2)cc1)=O)c1)c1Nc1nc(-c2ccccc2)ccn1 Chemical compound Cc(ncc(NC(c1ccc(CC2CCN(C)CC2)cc1)=O)c1)c1Nc1nc(-c2ccccc2)ccn1 DDROEHOVYPZJIV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93378207P | 2007-06-07 | 2007-06-07 | |
| US60/933,782 | 2007-06-07 | ||
| PCT/US2008/007167 WO2008153974A1 (en) | 2007-06-07 | 2008-06-06 | Novel heterocycle compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014116664A Division JP6017496B2 (ja) | 2007-06-07 | 2014-06-05 | 新規ヘテロ環化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010529132A JP2010529132A (ja) | 2010-08-26 |
| JP2010529132A5 true JP2010529132A5 (enExample) | 2011-07-21 |
| JP5559043B2 JP5559043B2 (ja) | 2014-07-23 |
Family
ID=40130063
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511212A Expired - Fee Related JP5559043B2 (ja) | 2007-06-07 | 2008-06-06 | 新規ヘテロ環化合物およびその使用 |
| JP2014116664A Expired - Fee Related JP6017496B2 (ja) | 2007-06-07 | 2014-06-05 | 新規ヘテロ環化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014116664A Expired - Fee Related JP6017496B2 (ja) | 2007-06-07 | 2014-06-05 | 新規ヘテロ環化合物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9062023B2 (enExample) |
| EP (1) | EP2166860B1 (enExample) |
| JP (2) | JP5559043B2 (enExample) |
| ES (1) | ES2607794T3 (enExample) |
| WO (1) | WO2008153974A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1469810A4 (en) | 2002-01-04 | 2009-01-14 | Univ Rockefeller | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS |
| JP5559043B2 (ja) * | 2007-06-07 | 2014-07-23 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 新規ヘテロ環化合物およびその使用 |
| EP2166858A4 (en) | 2007-06-07 | 2011-08-03 | Intra Cellular Therapies Inc | NEW HETEROCYCLIC COMPOUNDS AND ITS USE |
| TW201103904A (en) * | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
| CN107652269A (zh) * | 2016-07-26 | 2018-02-02 | 江苏豪森药业集团有限公司 | 甲磺酸氟马替尼中间体纯化方法 |
| AU2020232755A1 (en) * | 2019-03-05 | 2021-11-04 | Hongyi & Associates LLC. | Compounds for treating neurodegenerative diseases and cancers |
| CN116789643B (zh) * | 2023-06-25 | 2025-05-06 | 海南医学院 | 一种2-氨基嘧啶类化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| EP1469810A4 (en) | 2002-01-04 | 2009-01-14 | Univ Rockefeller | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS |
| GB0201508D0 (en) | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
| CN100343237C (zh) | 2002-06-28 | 2007-10-17 | 日本新药株式会社 | 酰胺衍生物及医药品 |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| AU2004246800B2 (en) | 2003-06-13 | 2008-12-04 | Novartis Ag | 2-aminopyrimidine derivatives as Raf kinase inhibitors |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| JP5520433B2 (ja) | 2004-01-21 | 2014-06-11 | エモリー ユニバーシティー | 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用 |
| CA2578122A1 (en) * | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| CN1939910A (zh) * | 2004-12-31 | 2007-04-04 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
| CN1972917B (zh) * | 2004-12-31 | 2010-08-25 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
| EP2166858A4 (en) | 2007-06-07 | 2011-08-03 | Intra Cellular Therapies Inc | NEW HETEROCYCLIC COMPOUNDS AND ITS USE |
| JP5559043B2 (ja) * | 2007-06-07 | 2014-07-23 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 新規ヘテロ環化合物およびその使用 |
| CN102271669A (zh) | 2008-11-13 | 2011-12-07 | 基因改造有限责任公司 | 非大脑组织中β-淀粉样肽负载的改性 |
-
2008
- 2008-06-06 JP JP2010511212A patent/JP5559043B2/ja not_active Expired - Fee Related
- 2008-06-06 ES ES08768240.7T patent/ES2607794T3/es active Active
- 2008-06-06 US US12/663,224 patent/US9062023B2/en active Active
- 2008-06-06 EP EP08768240.7A patent/EP2166860B1/en not_active Not-in-force
- 2008-06-06 WO PCT/US2008/007167 patent/WO2008153974A1/en not_active Ceased
-
2014
- 2014-06-05 JP JP2014116664A patent/JP6017496B2/ja not_active Expired - Fee Related
-
2015
- 2015-06-22 US US14/745,806 patent/US20160075683A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536833A5 (enExample) | ||
| JP2013526544A5 (enExample) | ||
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| JP2013519685A (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 | |
| JP2013519684A (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法 | |
| JP2013509392A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| JP2015504091A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2013508412A (ja) | ｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 | |
| JP2015503609A5 (enExample) | ||
| JP2017534664A5 (enExample) | ||
| JP2009526831A5 (enExample) | ||
| JP2019512533A5 (enExample) | ||
| MY168930A (en) | Azole derivative | |
| RU2013113634A (ru) | Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств | |
| JP2013544277A5 (enExample) | ||
| JP2020527173A5 (enExample) | ||
| RU2015101512A (ru) | Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5 | |
| JP2019534310A5 (enExample) | ||
| JP2017534663A5 (enExample) | ||
| RU2017112989A (ru) | Соединения и способы | |
| PH12016500427A1 (en) | Ethynyl derivatives |